ATP-regulated neuronal catecholamine uptake: a new mechanism

The norepinephrine transporter and its regulation

For many years, the norepinephrine transporter (NET) was considered a 'static' protein that contributed to the termination of the action of norepinephrine in the synapse of noradrenergic neurons. The concept that the NET is dynamically regulated, adjusting noradrenergic transmission by changing its function and/or expression, was considered initially in the mid 1980s. Since that time, a plethora of studies demonstrate that the NET is regulated by several intracellular and extracellular signaling molecules, and that phosphorylation of the NET is a major pathway regulating its cell surface expression and thereby its function. The NET is a target of action of a number of drugs that are used long-term therapeutically or abused chronically. This has driven numerous investigations of how the NET and its function are regulated by long-term exposure to drugs. While repeated exposure to many drugs has been shown to affect NET function and expression, the intracellular mechanisms for these effects remains elusive.

Cytotoxicity of organophosphate anticholinesterases

Organophosphate (OP) anticholinesterases were found to modulate metabolic activities of human neuroblastoma cells and hepatocytes, which was detectable by the Cytosensor microphysiometer. The nerve gas ethyl-S-2-diisopropylaminoethyl methylphosphorothiolate (VX), at 10 microM, produced significant reduction in cell metabolism within 2 min, as measured by changes in the acidification rate of the medium. The reduction was dose- and time-dependent and irreversible after 4 h of exposure. Two alkaline degradation products of VX produced no cytotoxicity. Exposure for 24 h to 3 microM VX caused 36% and 94% irreversible loss of metabolism in hepatocytes and neuroblastoma cells, respectively. The insecticides parathion and chlorpyrifos stimulated hepatocyte metabolism but inhibited neuroblastoma cells. Their oxons were more active. Exposure of neuroblastoma cells for 4 h to VX, parathion, paraoxon, diisopropylfluorophosphate or chlorpyrifos gave an LC50 of 65, 775, 640, 340, or 672 microM, respectively, whereas 24 h gave an LC50 of 0.7, 3.7, 2.5, 29, and 31 microM, respectively. Preincubation of hepatocytes with phenobarbital enhanced their response to parathion and VX due to metabolic bioactivation. Atropine partially blocked the effects of VX and paraoxon on both cell types, which suggests the involvement of a muscarinic receptor as the target for cytotoxicity. There was no correlation between OP in vivo neurotoxicity and in vitro cytotoxicity. It is suggested that the former results from their cholinesterase inhibition, while the latter results from action on different targets and requires much higher concentrations.

Identification of the major transport pathway for the parkinsonism-inducing neurotoxin 1-methyl-4-phenylpyridinium

1-Methyl-4-phenylpyridinium is a potent parkinsonism-inducing neurotoxin which has become a valuable tool for the examination of the mechanisms and therapeutic treatment strategies for Parkinson's syndrome. Recently, it has been found that physiological levels of extracellular ATP (0.1-1 mM) stimulate dopamine uptake into both rat and bovine brain synaptosomes and rat pheochromocytoma cells in a dose-dependent manner. In this study we report that physiological levels of extracellular ATP (0.1-2 mM) stimulate the transport of 1-methyl-4-phenylpyridinium into the pheochromocytoma cell line by 270% over basal levels. Kinetically, the presence of ATP increases both the K(m) and Vmax of 1-methyl-4-phenylpyridinium transport. In addition, 1-methyl-4-phenylpyridinium is far more effective at inhibiting ATP-stimulated dopamine transport (IC50 = 11 microM) than basal dopamine transport (IC50 100 microM) into pheochromocytoma cells. These data show that the ATP-regulated 1-methyl-4-phenylpyridinium transport pathway is the major component (approximately 95%) of total 1-methyl-4-phenylpyridinium transport, and provide the first evidence for the involvement of extracellular ATP in the bulk transport of 1-methyl-4-phenylpyridinium.

Cation requirements of basal and ATP-regulated dopamine transport in rat pheochromocytoma cells

The transport of dopamine into presynaptic nerve terminals is the primary mechanism for the termination of dopaminergic neurotransmission. This transport process has recently been found to be composed of two components, a basal dopamine transport pathway which exists in the absence of extracellular ATP and an ATP-regulated moiety which comprises approximately 66% of the total transport system [Cao C. J. et al. (1990) Biochem. Pharmac. 39, R9-R14; Cao C. J. et al. (1989) Biochemistry 8, 207-220; Dunigan C. D. and Shamoo A. E. (1995) Neuroscience 65, 1-4; Eshleman A. et al. (1995) Life Sci. 56, 1613-1621]. Using a rat pheochromocytoma cell line and a Krebs bicarbonate buffering system, the present study examined the effect of several cations on both basal and ATP-regulated dopamine transport. In the absence of extracellular ATP, dopamine transport had an absolute dependence on the presence of Na+, but exhibited no requirement for Mg2+. Kinetically, the addition of 120 mM NaCl increased the Vmax of basal dopamine transport by approximately 150%. In contrast, the ATP-regulated dopamine transport pathway displayed a different sensitivity to Na+ and was completely dependent upon the presence of Mg2+. The addition of 1.2 mM MgSO4 increased the Vmax of transport in the presence of 0.7 mM extracellular ATP by 222%. Both basal and ATP-regulated transport were unaffected by the removal of either Ca2+ or K+ from the assay buffer. When the effects of ouabain, a potent inhibitor of Na+, K(+)-ATPase, were tested in the rat pheochromocytoma cell model, it was found that concentrations of ouabain as high as 1 mM were ineffective at inhibiting either the basal or ATP-regulated dopamine transport components. These results imply that the Na+ gradient supplied by Na+, K(+)-ATPase is not the sole provider of energy needed to drive either transport process. The ionic requirements of the basal and ATP-regulated dopamine transport pathways demonstrate the distinction between the two transport processes. In addition, the ionic dependency profile of the ATP-regulated moiety has provided some mechanistic insights into ATP-regulated catecholamine uptake, as the absolute Mg2+ requirement and the ineffectiveness of Ca2+ argues against the involvement of either purinergic receptors or a Ca(2+)-dependent, Mg(2+)-independent ectokinase in the ATP-regulated transport system.

Li+ stimulates ATP-regulated dopamine uptake in PC12 cells

Increased levels of dopamine have been associated with schizophrenia and mania; conversely, decreased levels of dopamine are associated with depression. Since the main mechanism for the termination of dopamine's pharmacological action is by re-uptake into the presynaptic cell, the speed of dopamine transport dramatically influences the concentration of dopamine present in the synaptic cleft, which in turn could determine brain disorders. Our preliminary studies have found that ATP can stimulate dopamine transport in rat synaptosomal preparation. We have also observed this ATP-regulated moiety of the dopamine uptake system when tested in PC12 cells. The large magnitude of ATP stimulation suggests that this dopamine uptake pathway may be important in the etiology and treatment of brain disorders. In order to test the relevance of ATP-stimulated dopamine uptake, we tested the effect of lithium salts on this system. Lithium chloride, one of the first drugs used in the treatment of mania, has become one of the most important agents utilized for the treatment of manic-depression and many schizoeffective disorders. Unfortunately, despite all efforts that have been made to explain lithium's mode of action, a clear cut biochemical mechanism has not been defined. We have found that lithium chloride, at therapeutic levels, is able to stimulate the ATP-regulated component of the dopamine uptake system by 49%. The further enhancement of dopamine re-uptake by lithium ions is consistent with its therapeutic effect. It is suggested that any substance that facilitates dopamine re-uptake could be of great importance in defining a useful treatment for mania and schizophrenia, as well as depression.

ATP enhances catecholamine uptake into PC12 cells

Catecholamine uptake into PC12 cells, in the presence and absence of ATP, was measured in a bicarbonate-buffered Krebs Ringer. ATP enhanced significantly the uptake in a dose-dependent manner with maximal uptake at 1-3 mM. ATP increased the Vmax of uptake by 3-5 fold for both dopamine and norepinephrine, without a significant change in the Km. ATP-stimulated amine uptake was temperature- and Na(+)-dependent and robust in bicarbonate, but not in HEPES buffer. The ability to enhance uptake was not observed with metabolites of ATP. GTP and UTP were equally effective to ATP in enhancing CA uptake. This uptake was less sensitive to uptake inhibitors in bicarbonate buffered media than in phosphate-buffered media, and more so in the presence of ATP. It is suggested that ATP is an allosteric modulator of the transporter and that a stable ATP analog, with ATP-like enhancement of dopamine uptake, may be an effective cocaine antagonist.

Dimethylthiourea prevents MPTP-induced decrease in [3H]dopamine uptake in rat striatal slices

To determine whether oxygen free radicals are involved in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity, the effect of dimethylthiourea (DMTU), an effective hydroxyl radical scavenger, on MPTP-induced changes of [3H]dopamine uptake was investigated in rat striatal slices. The uptake of [3H]dopamine was decreased by MPTP treatment, and DMTU prevented the MPTP-induced decrease of [3H]dopamine uptake in a dose-dependent manner. The highest dose of DMTU used in this study completely prevented the MPTP-induced decrease of [3H]dopamine uptake. These results indicate that free radicals play a major role in the pathogenetic mechanism of MPTP-induced neurotoxicity.

The neuronal transport mechanism for noradrenaline is not influenced by the ATP analogue ATP gamma S

Noradrenaline is taken up in noradrenergic neurones via a desipramine-sensitive transport system (uptake1). There are reports which describe the activity of uptake1 being increased by extracellular ATP and ATP gamma S. This was attributed to a protein kinase-mediated mechanism. We reevaluated this phenomenon since a modulation of uptake1 by extracellular ATP would be of great physiological relevance. In clonal rat pheochromocytoma cells (PC12) we determined the kinetic parameters, Km and Vmax, of noradrenaline transport in the absence and presence of ATP gamma S. The addition of 0.1 mumol/L ATP gamma S had no effect on initial rates of specific noradrenaline transport. Only a slightly increased non-specific noradrenaline flux in the presence of ATP gamma S could be observed. On the basis of our results, there is no evidence for the modulation of the uptake1 carrier by ATP gamma S.

Extracellular ATP stimulates calcium influx in neuroblastoma x glioma hybrid NG108-15 cells

ATP-induced changes in the intracellular Ca2+ concentration ([Ca2+]i) in neuroblastoma x glioma hybrid NG108-15 cells were studied. Using the fluorescent Ca2+ indicator fura-2, we have shown that the [Ca2+]i increased in response to ATP. ATP at 3 mM caused the greatest increased in [Ca2+]i, whereas at higher concentrations of ATP the response became smaller. Two nonhydrolyzable ATP analogues, adenosine 5'-thiotriphosphate and 5'-adenylyl-beta, gamma-imidodiphosphate, could not trigger significant [Ca2+]i change, but they could block the ATP effect. Other adenine nucleotides, including ADP, AMP, alpha beta-methylene-ATP, beta, gamma-methylene-ATP, and 2-methylthio-ATP, as well as UTP and adenosine, all had no effect on [Ca2+]i at 3 mM. In the absence of extracellular Ca2+, the effect of ATP was inhibited totally, but could be restored by the addition of Ca2+ to the cells. Upon removal of Mg2+, the maximum increase in [Ca2+]i induced by ATP was enhanced by about 42%. Ca(2+)-channel blockers partially inhibited the ATP-induced [Ca2+]i rise. The ATP-induced [Ca2+]i rise was not affected by thapsigargin pretreatment, though such pretreatment blocked bradykinin-induced [Ca2+]i rise completely. No heterologous desensitization of [Ca2+]i rise was observed between ATP and bradykinin. The magnitude of the [Ca2+]i rise induced by ATP increased between 1.5 and 3.1 times when external Na+ was replaced with Tris, N-methyl-D-glucamine, choline, or Li+. The addition of EGTA or verapamil to cells after their maximum response to ATP immediately lowered the [Ca2+]i to the basal level in Na(+)-containing or Na(+)-free Tris solution.(ABSTRACT TRUNCATED AT 250 WORDS)

A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine

A study of Na+ and Cl- as co-substrates in dopamine uptake into striatal suspensions and inhibition of dopamine uptake by cocaine was made by monitoring the initial velocity of the uptake of exogenously added non-radioactively labeled dopamine using a rotating disk electroanalytical technique with 50 msec resolution. Dopamine, in the concentration range of 0.025 to 4.00 microM, was found to be taken up rapidly into the tissue phase of striatal suspensions following the apparent zero order rate law for the first 25 sec. The observed, dopamine concentration-dependent, initial velocity data were first analyzed graphically using the Eadie-Hofstee transformation of the Michaelis-Menten kinetic equation and, subsequently, using all of the velocity data and the results of the graphical analyses, by non-linear curve fitting. Dopamine uptake was found to be first order in dopamine with a Vmax of 582 pmol/sec/g wet weight and a Km of 1.2 microM. The results of experiments in which choline and isethionate were substituted for Na+ and Cl-, respectively, suggested that the uptake process is second order in Na+ and first order in Cl-. Multisubstrate analyses of the initial velocities of uptake over the concentration range of 0.025 to 1.5 microM dopamine suggested that the mechanism of binding of dopamine to the uptake carrier is a partially random, sequential mechanism where dopamine or Na+ binds first with the uptake carrier and Cl- binds last. Cocaine was found to uncompetitively inhibit dopamine uptake and competitively inhibit both Na+ and Cl- binding (apparent Km values: 131 and 51 mM, respectively), suggesting that the mechanism of cocaine inhibition may be to bind to the dopamine occupied uptake carrier complex at the Na+ binding site.